Dry AMD Treatment Breakthroughs: Santen, Allergan, and the Path to Cures

Technological Advancements in Dry Age-Related Macular Degeneration (AMD)

One of the most promising technological advancements in Dry AMD treatment is the development of gene therapy. Companies like Santen Pharmaceuticals Inc. and Allergan plc are actively researching gene therapy approaches to target the underlying genetic causes of Dry AMD. These therapies involve introducing corrective genes into the affected cells to restore their function.

Another area of active research is cell therapy. Bausch Health and Alimera Science Inc. are exploring the use of stem cells to regenerate damaged retinal cells and improve vision in patients with Dry AMD.

Additionally, there are ongoing efforts to develop new drug delivery methods to improve the efficacy and safety of Dry AMD treatments. Companies like Phio Pharmaceuticals Corp and Ocumension Therapeutics Co. Ltd are investigating novel drug delivery systems, such as nanoparticles and microspheres, to deliver therapeutic agents directly to the affected area of the eye.

Companies developing Dry AMD treatments are focusing on several key R&D priorities:

The Dry AMD market has seen several significant mergers and acquisitions in recent years, as companies seek to expand their product portfolios and gain access to new technologies. For example, Allergan plc acquired Tobira Therapeutics in 2018 to gain access to its pipeline of liver diseases and Dry AMD treatments. Additionally, Belite Bio Inc. was acquired by Kubota Vision Inc. in 2021, combining their efforts to develop innovative therapies for Dry AMD.

Companies developing Dry AMD treatments face several regulatory challenges, including:

However, there are also significant opportunities for companies that can successfully develop and commercialize innovative Dry AMD treatments. The growing prevalence of Dry AMD and the unmet need for effective therapies create a large market potential.

The Dry AMD market is expected to continue to grow in the coming years, driven by the increasing prevalence of the disease and the development of new and more effective treatments. According to Market Research Future, the global Dry AMD market is projected to reach USD 17.92 billion by 2032, with a CAGR of 8.2% during the forecast period (2023-2032).

For more information visit at MarketResearchFuture

Other Trending Reports

Hospital Beds Market

Dental 3D Printing Market

Nanobody Market

Remote Patient Monitoring Market

Pain Management Market